DGAP-News
CureVac Provides Supervisory Board Update
DGAP-News: CureVac / Key word(s): Personnel
CureVac Provides Supervisory Board Update |
"I would like to express my deepest gratitude and respect to Ingmar for his vision to advance new vaccine and therapeutic opportunities utilizing mRNA technology, and his tireless dedication in building CureVac around this vision," said Jean Stéphenne, Chairman of the Supervisory Board of CureVac. "Ingmar's pioneering work in making mRNA accessible has helped to form the basis of a key technology that is now addressing today's COVID-19 pandemic as well as future medical challenges in vaccines and therapeutics."
The Company further announced that Dr. Timothy M. Wright is resigning from his role as Independent Director from CureVac's Supervisory Board to focus on his own professional endeavors. His resignation will become effective on June 24, 2021. Dr. Wright joined the CureVac Supervisory Board in June 2018 and served as member of the Audit Committee.
"On behalf of our Board of Directors, I wish to thank Timothy for investing his valuable time, talent, passion and wisdom to grow the Company. Timothy's experience in drug development has helped shape the Company and prepare it for a successful future," added Jean Stéphenne, Chairman of the Supervisory Board of CureVac.
About CureVac
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule
for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable
of fighting a broad range of diseases. Based on its proprietary technology, the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody
therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 700
people at its sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.